


SUPPLEMENTAL MATERIAL

Supplemental Table 1. Primers used in the present study.

Gene	Forward primer (5' -3')	Reverse primer (5' -3')
LDLR	CAGACTGCAAGGACAAGTCA	GAG CCA TCT GCA CAC TGG AA
VLDLR	CCACAGCAGTATCAGAAGTC	GCCATCACTAAGAGC AAGAG
LPL	AGTGTTTGTGAAATGCCATGA CA	CGGATGCTTTCTTCTCTTGTTG
APOA1	GTGGCTCTGGTCTTCCTGAC	ACGGTTGAACCCAGAGTGTC
CD36	GCC AAG CTA TTG CGA CAT GA	AGA ATC TCA ATG TCC GAG ACT
SREBP1	CCG TGG GCT GAG GAA GGA	TGT GTA CTT GCC CAT GGC A
SREBP2	CATCCCTTGGGCCAGAAGTT	TCCTTGGCTGCTGACTTGATC
Abca1	AACAGTTTGTGGCCCTTTTG	AGTTCCAGGCTGGGGTACTT
HMGR	TCTGGCAGTCAGTGGGAACTATT	CCTCGTCCTTCGATCCAATTT
CYP7A1	CAGTGAAGGTCATGCTGGAG	CGCAATGAAGAAGGTGACAA
SR-BI	TCCCTCATCAAGCAGCAGGT	TTCCACATCCCGAAGGACA

Supplemental Figure 1.



Supplemental Figure 1. Histopathological analysis showing Masson's Trichrome stained left coronary artery (LCA) of control ApoE^{-/-} mouse on a chow diet (A), Apo E^{-/-} on high fat high cholesterol (HFHC) diet plus vehicle (Placebo) (B), Apo E^{-/-} on HFHC diet plus treatment with 5 (C) and 10 mpk of D-DPMP (D) respectively. Quantification of the cross sectional area of LCA (E). The placebo mice (E) show a significant increase in the cross sectional area (CSA), loss of smooth muscle cells, perivascular fibrosis, damaged wall, thrombosis and occlusion as compared to control and treated mice. The 5 and 10 mpk of D-DPMP treated mice show a dose dependent decline in cross sectional area and are not significantly different to control mice.